COVID-19患者活动性动脉出血的栓塞治疗:多中心研究
该多中心回顾性研究评估经导管动脉栓塞治疗COVID-19患者动脉出血的技术成功率与30天生存率,共纳入53例患者(66次血管造影)。初始栓塞技术成功率为98.1%,ECMO患者30天生存率显著低于非ECMO患者(45.2% vs. 86.4%,p=0.004),且再出血风险更高(32.3% vs. 4.5%,p=0.02)。结论认为栓塞可行、安全、有效,ECMO与不良预后相关。
要点
- COVID-19合并动脉出血行经导管栓塞技术成功率高(98.1%),可作为可行治疗选择。
- ECMO患者栓塞后30天生存率显著更低(45.2% vs 86.4%),再出血风险更高。
- 抗凝治疗未显示与更高死亡率相关,不应视为栓塞禁忌。
核心结论
- 经导管动脉栓塞是COVID-19患者动脉出血可行、安全且有效的治疗方式。
- 接受ECMO治疗的患者30天生存率显著低于非ECMO患者,且栓塞后再出血风险更高。
- 抗凝治疗未被识别为增加死亡率的危险因素。
研究设计与样本
- 多中心回顾性研究,纳入2020年4月至2022年7月因动脉出血接受经导管栓塞的COVID-19患者53例(年龄57.3±14.3岁,37例男性),共行66次血管造影。
- 分析技术成功率与生存率,比较不同患者组间30天生存率,采用卡方检验和Fisher精确检验分析分类变量关联。
诊断标准与关键数值
- 初始栓塞技术成功率为98.1%(52/53)。
- 20.8%(11/53)患者因新发动脉出血需再次栓塞。
- ECMO患者30天生存率45.2%(14/31),非ECMO患者86.4%(19/22),p=0.004。
临床应用与阅片要点
- 对COVID-19合并活动性动脉出血患者,可考虑经导管栓塞作为止血手段,技术成功率高。
- ECMO支持患者栓塞后需密切监测再出血,因其风险显著增高且生存率较低。
- 抗凝治疗不应作为放弃栓塞或视为高死亡风险的依据。
局限性
- 回顾性研究设计,存在选择偏倚和信息偏倚可能。
- 样本量较小(53例),部分亚组分析例数少(如非抗凝组仅7例),统计效能有限。
- 未报告栓塞具体血管分布、出血部位及并发症等影像介入细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: The purpose of this study was to assess the efficacy of transarterial embolization in COVID-19 patients with an arterial bleeding and to investigate differences between various patient groups concerning survival.
METHOD: We retrospectively reviewed COVID-19 patients undergoing transarterial embolization due to an arterial bleeding in a multicenter study from April 2020 to July 2022 and analyzed the technical success of embolization and survival rate. 30-day survival between various patient groups was analyzed. The Chi- square test and Fisher's exact test were used for testing association between the categorical variables.
RESULTS: 53 COVID-19 patients (age: 57.3 ± 14.3 years, 37 male) received 66 angiographies due to an arterial bleeding. The initial embolization was technically successful in 98.1% (52/53). In 20.8% (11/53) of patients, additional embolization was necessary due to a new arterial bleeding. A majority of 58.5% (31/53) had a severe course of COVID-19 infection necessitating ECMO-therapy and 86.8% (46/53) of patients received anticoagulation. 30-day survival rate in patients with ECMO-therapy was significantly lower than without ECMO-therapy (45.2% vs. 86.4%, p = 0.004). Patients with anticoagulation did not have a lower 30-day survival rate than without anticoagulation (58.7% vs. 85.7%, p = 0.23). COVID-19 patients with ECMO-therapy developed more frequently a re-bleeding after embolization than non-ECMO-patients (32.3% vs. 4.5%, p = 0.02).
CONCLUSIONS: Transarterial embolization is a feasible, safe, and effective procedure in COVID-19 patients with arterial bleeding. ECMO-patients have a lower 30-day survival rate than non-ECMO-patients and have an increased risk for re-bleeding. Treatment with anticoagulation could not be identified as a risk factor for higher mortality.
引用
- Steinberg, Auer, Gebauer, et al. Embolization of active arterial bleeding in COVID-19 patients: A multicenter study. Eur J Radiol. 2023. PMID: 37269571. doi:10.1016/j.ejrad.2023.110892
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。